Cancer immunotherapy - revisited

被引：323

作者：

Lesterhuis, W. Joost ^{[1
]}

Haanen, John B. A. G. ^{[2
,3
]}

Punt, Cornelis J. A. ^{[1
]}

机构：

[1] Radboud Univ Nijmegen Med Ctr, Dept Med Oncol, NL-6500 HB Nijmegen, Netherlands

[2] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Div Med Oncol, NL-1066 CX Amsterdam, Netherlands

[3] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Div Immunol, NL-1066 CX Amsterdam, Netherlands

来源：

NATURE REVIEWS DRUG DISCOVERY | 2011年 / 10卷 / 08期

关键词：

REGULATORY T-CELLS; BACILLUS-CALMETTE-GUERIN; ACTIVATED KILLER-CELLS; METASTATIC MELANOMA; DENDRITIC CELLS; RECOMBINANT INTERLEUKIN-2; ADOPTIVE IMMUNOTHERAPY; SELECTIVE DEPLETION; CLINICAL-RESPONSES; ANTITUMOR-ACTIVITY;

D O I：

10.1038/nrd3500

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Our insight into antitumour immune responses has increased considerably during the past decades, yet the development of immunotherapy as a treatment modality for cancer has been hampered by several factors. These include difficulties in the selection of the optimal dose and schedule, the methods of evaluation, and financial support. Although durable clinical remissions have been observed with various immunotherapeutic strategies, the percentage of patients who benefited from these interventions has remained too small to justify the general use of such strategies. However, the recent positive results of clinical trials with novel immunoactive drugs as well as the unexpected finding of a positive interaction between immunotherapy and chemotherapy may herald a new era for the immunotherapy of cancer.

引用

页码：591 / 600

页数：10

共 115 条

[21] Landmark approval for Dendreon's cancer vaccine [J].

DeFrancesco, Laura .

NATURE BIOTECHNOLOGY, 2010, 28 (06) :531-532

[22] In situ tumor ablation creates an antigen source for the generation of antitumor immunity [J].

den Brok, MHMGM ;

Sutmuller, RPM ;

van der Voort, R ;

Bennink, EJ ;

Figdor, CG ;

Ruers, TJM ;

Adema, GJ .

CANCER RESEARCH, 2004, 64 (11) :4024-4029

[23] Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients [J].

Desar, Ingrid M. E. ;

Jacobs, J. F. M. ;

Hulsbergen-vandeKaa, Christina A. ;

Oyen, Wim J. G. ;

Mulders, Peter F. A. ;

van der Graaf, Winette T. A. ;

Adema, Gosse J. ;

van Herpen, Carla M. L. ;

de Vries, I. J. M. .

INTERNATIONAL JOURNAL OF CANCER, 2011, 129 (02) :507-512

[24] Immune Therapy for Cancer [J].

Dougan, Michael ;

Dranoff, Glenn .

ANNUAL REVIEW OF IMMUNOLOGY, 2009, 27 :83-117

[25] Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma [J].

Dudley, ME ;

Wunderlich, JR ;

Yang, JC ;

Sherry, RM ;

Topalian, SL ;

Restifo, NP ;

Royal, RE ;

Kammula, U ;

White, DE ;

Mavroukakis, SA ;

Rogers, LJ ;

Gracia, GJ ;

Jones, SA ;

Mangiameli, DP ;

Pelletier, MM ;

Gea-Banacloche, J ;

Robinson, MR ;

Berman, DM ;

Filie, AC ;

Abati, A ;

Rosenberg, SA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) :2346-2357

[26]

Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514

[27] Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial [J].

Eggermont, AMM ;

Suciu, S ;

MacKie, R ;

Ruka, W ;

Testori, A ;

Kruit, W ;

Punt, CJA ;

Delauney, M ;

Sales, F ;

Groenewegen, G ;

Ruiter, DJ ;

Jagiello, I ;

Stoitchkov, K ;

Keilholz, U ;

Lienard, D .

LANCET, 2005, 366 (9492) :1189-1196

[28] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[29] The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation [J].

Farinha, Pedro ;

Al-Tourah, Abdulwahab ;

Gill, Karamjit ;

Klasa, Richard ;

Connors, Joseph M. ;

Gascoyne, Randy D. .

BLOOD, 2010, 115 (02) :289-295

[30] Inhibition of Mutated, Activated BRAF in Metastatic Melanoma [J].

Flaherty, Keith T. ;

Puzanov, Igor ;

Kim, Kevin B. ;

Ribas, Antoni ;

McArthur, Grant A. ;

Sosman, Jeffrey A. ;

O'Dwyer, Peter J. ;

Lee, Richard J. ;

Grippo, Joseph F. ;

Nolop, Keith ;

Chapman, Paul B. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (09) :809-819

← 1 2 3 4 5 6 7 8 9 10 →